MX2023003996A - Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. - Google Patents

Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.

Info

Publication number
MX2023003996A
MX2023003996A MX2023003996A MX2023003996A MX2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A MX 2023003996 A MX2023003996 A MX 2023003996A
Authority
MX
Mexico
Prior art keywords
bcr
inhibition
tyrosine kinases
abl tyrosine
compounds
Prior art date
Application number
MX2023003996A
Other languages
English (en)
Inventor
Joseph P Lyssikatos
Li Ren
Samuel Kintz
Original Assignee
Enliven Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enliven Inc filed Critical Enliven Inc
Publication of MX2023003996A publication Critical patent/MX2023003996A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente descripción se refiere a compuestos y composiciones para la inhibición de tirosina cinasas Bcr-Abl, métodos de preparación de dichos compuestos y composiciones, y su uso en el tratamiento de diversos tipos de cáncer, como la leucemia mieloide crónica (LMC).
MX2023003996A 2020-10-05 2021-10-04 Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl. MX2023003996A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087780P 2020-10-05 2020-10-05
PCT/US2021/071692 WO2022076973A1 (en) 2020-10-05 2021-10-04 7-azaindole compounds for inhibition of bcr-abl tyrosine kinases

Publications (1)

Publication Number Publication Date
MX2023003996A true MX2023003996A (es) 2023-06-15

Family

ID=81125544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003996A MX2023003996A (es) 2020-10-05 2021-10-04 Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.

Country Status (8)

Country Link
US (1) US20240043420A1 (es)
EP (1) EP4225741A1 (es)
JP (1) JP2023545219A (es)
KR (1) KR20230104782A (es)
CN (1) CN116438182A (es)
IL (1) IL301740A (es)
MX (1) MX2023003996A (es)
WO (1) WO2022076973A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116063212B (zh) * 2023-01-28 2023-06-27 山东国邦药业有限公司 一种4-苯硫基-1,2-苯二胺的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0330043D0 (en) * 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
FR2941948B1 (fr) * 2009-02-12 2013-04-05 Nova Decision Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src
FR3000492B1 (fr) * 2012-12-28 2015-09-11 Oribase Pharma Nouveaux derives azaindole en tant qu'inhibiteurs multikinases

Also Published As

Publication number Publication date
WO2022076973A1 (en) 2022-04-14
IL301740A (en) 2023-05-01
JP2023545219A (ja) 2023-10-26
EP4225741A1 (en) 2023-08-16
US20240043420A1 (en) 2024-02-08
CN116438182A (zh) 2023-07-14
KR20230104782A (ko) 2023-07-10

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
PH12018500587A1 (en) Pyrazolopyrimidine derivatives as btk inhibitors for the treatment of cancer
PH12019502138A1 (en) Compounds and compositions for treating hematological disorders
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
PH12018502535A1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
NZ722326A (en) Tricyclic compounds as anticancer agents
MX2021003517A (es) Composiciones de inhibidor de tirosina quinasa, metodos de fabricacion y metodos de uso.
JO3794B1 (ar) المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
AR067505A1 (es) Derivados de pirimidinil-piridazinona
PH12020550457A1 (en) Compounds and compositions for treating hematological disorders
WO2017216772A3 (en) Methods and compositions for treating breast and prostate cancer
PH12021550382A1 (en) Tetrahydropyridopyrimidine derivatives as ahr modulators
PH12020500343A1 (en) Pyruvate kinase activators for use in treating blood disorders
DOP2011000129A (es) 1h-imidazol-2-il-piperidin-1-il como inhibidores de cinasa akt y p70 s6
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
PH12020551853A1 (en) Axl kinase inhibitors and use of the same
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
WO2019023315A3 (en) RAC INHIBITORS
MX2023003996A (es) Compuestos de 7-azaindol para la inhibicion de tirosina cinasas bcr-abl.
WO2018218197A3 (en) ATR KINASE INHIBITORS BASED ON TETRAHYDROPYRIDO [4,3-D] PYRIMIDINE
MX2023003995A (es) Compuestos de 5-y 6-azaindol para la inhibicion de tirosina cinasas bcr-abl.
PH12021551276A1 (en) Combination therapy for the treatment of cancer